New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

In this video interview, Michael Andreini, president and CEO of the Multiple Myeloma Research Foundation, highlights how the ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The ...

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

This information is clinically relevant because if a patient continues to have MRD-positive status after treatment with isatuximab-VRd, then a change of therapy may prolong progression-free survival.

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

Over the past two decades the paradigm of multiple myeloma therapy has changed dramatically from conventional chemotherapy and autologous stem cell transplant (ASCT) to combination regimens of ...

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...